Skip to content
10-Q

Quarterly Report

INTEGRATED BIOPHARMA INC INBP

0001437749-25-016802

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · May 14, 2025 30.3M sh
Cash And Equivalents Q3 2025 · Mar 31, 2025 $2.96M
Cash And Equivalents Q3 2025 · Jun 30, 2024 $1.68M
Current Liabilities Q3 2025 · Mar 31, 2025 $4.98M
Current Liabilities Q3 2025 · Jun 30, 2024 $6.12M
Total Liabilities Q3 2025 · Mar 31, 2025 $5.27M
Total Liabilities Q3 2025 · Jun 30, 2024 $6.97M
Current Assets Q3 2025 · Mar 31, 2025 $18.55M
Current Assets Q3 2025 · Jun 30, 2024 $17.88M
Total Assets Q3 2025 · Mar 31, 2025 $25.66M
Total Assets Q3 2025 · Jun 30, 2024 $26.21M
Shares Diluted restated Q3 2025 · Mar 31, 2024 30.74M sh
Shares Diluted Q3 2025 · Mar 31, 2024 30.05M sh
Capex Q3 2025 · Mar 31, 2024 $407K
Operating Cash Flow Q3 2025 · Mar 31, 2024 $1.13M
Stockholders Equity Q3 2025 · Mar 31, 2024 $18.91M
Stockholders Equity Q3 2025 · Dec 31, 2023 $18.57M
Stockholders Equity Q3 2025 · Sep 30, 2023 $18.89M
Stockholders Equity Q3 2025 · Jun 30, 2023 $18.86M
Eps Diluted Q3 2025 · Mar 31, 2024 $0.01
Eps Diluted Q3 2025 · Mar 31, 2024 −$0.01
Eps Basic Q3 2025 · Mar 31, 2024 $0.01
Eps Basic Q3 2025 · Mar 31, 2024 −$0.01
Sga Expense Q3 2025 · Mar 31, 2024 $893K
Sga Expense Q3 2025 · Mar 31, 2024 $2.75M
Net Income Q3 2025 · Mar 31, 2024 $285K
Net Income Q3 2025 · Mar 31, 2024 −$156K
Net Income Q3 2025 · Dec 31, 2023 −$382K
Net Income Q3 2025 · Sep 30, 2023 −$59K
Operating Income Q3 2025 · Mar 31, 2024 $355K
Operating Income Q3 2025 · Mar 31, 2024 −$151K
Gross Profit Q3 2025 · Mar 31, 2024 $1.25M
Gross Profit Q3 2025 · Mar 31, 2024 $2.6M
Cost Of Revenue Q3 2025 · Mar 31, 2024 $11.9M
Cost Of Revenue Q3 2025 · Mar 31, 2024 $34.97M